KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash & Current Investments (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Cash & Current Investments data on record, last reported at $819.7 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 8.43% year-over-year to $819.7 million; the TTM value through Dec 2025 reached $819.7 million, up 8.43%, while the annual FY2025 figure was $819.7 million, 8.43% up from the prior year.
  • Cash & Current Investments reached $819.7 million in Q4 2025 per ACAD's latest filing, down from $847.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $847.0 million in Q3 2025 and bottomed at $345.9 million in Q3 2023.
  • Average Cash & Current Investments over 5 years is $544.9 million, with a median of $510.8 million recorded in 2021.
  • Peak YoY movement for Cash & Current Investments: fell 22.81% in 2022, then surged 72.26% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $520.7 million in 2021, then dropped by 19.95% to $416.8 million in 2022, then rose by 5.29% to $438.9 million in 2023, then soared by 72.26% to $756.0 million in 2024, then rose by 8.43% to $819.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $819.7 million in Q4 2025, $847.0 million in Q3 2025, and $762.0 million in Q2 2025.